(Q44671785)

5 December 2017

title

Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection (English)

1 reference

5 December 2017

main subject

anti-retroviral agent

0 references

1 reference

1

1 reference

5 December 2017

4

1 reference

5 December 2017

Pei-Jer Chen

2

1 reference

5 December 2017

Mao-Yuan Chen

3

1 reference

5 December 2017

Shan-Chwen Chang

5

1 reference

5 December 2017

An-Lung Chang

6

1 reference

5 December 2017

Ding-Shinn Chen

7

1 reference

5 December 2017

publication date

1 December 2003

1 reference

5 December 2017

published in

Journal of Hepatology

1 reference

5 December 2017

volume

39

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

1028-1035

1 reference

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Natural history of HIV infection in the era of combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Hepatitis B virus infection in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Outcome of Hepatitis B Virus Infection in Homosexual Men and Its Relation to Prior Human Immunodeficiency Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

From hepatitis to hepatoma: lessons from type B viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male population

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Expression of hepatitis B surface and core antigens and transforming growth factor‐a in “oval cells” of the liver in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Oval cell numbers in human chronic liver diseases are directly related to disease severity.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900416-1

7 January 2021

10.1016/S0168-8278(03)00416-1

Identifiers

DOI

1 reference

5 December 2017

1 reference